Glucarpidase to combat toxic levels of methotrexate in patients

In January 2012, glucarpidase (Voraxaze(®)) received approval from the US Food and Drug Administration for intravenous treatment of toxic plasma methotrexate concentrations due to impaired renal clearance. Methotrexate, an antifolate agent, has been used for over 60 years in the treatment of various...

Descripción completa

Detalles Bibliográficos
Autor principal: Green, Jacalyn M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511185/
https://www.ncbi.nlm.nih.gov/pubmed/23209370
http://dx.doi.org/10.2147/TCRM.S30135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3511185/
https://www.ncbi.nlm.nih.gov/pubmed/23209370
http://dx.doi.org/10.2147/TCRM.S30135

Ejemplares similares